undamentalytics Newsletter
Sign in

Lifestance Health Group, Inc. (LFST) stock

Add to watchlist

Add holding +

NASDAQ: LFST Nasdaq Health Care Services Next results ~November 5, 2026

Lifestance Health Group, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Lifestance Health Group, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 31 sales by directors and officers, last 12 monthsInsider trades
  • Funds198 adding, 81 cuttingOf 43 active managers that changed their stake, 27 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Lifestance Health Group files

Where Lifestance Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.58bn, up 20.4% on a year earlier, faster than the 16.5% growth a quarter earlier. Free-cash-flow margin rose to 11.0% from 9.1% a year earlier. Operating margin widened to 4.9% from -0.0%. The diluted share count is up 2.0% on a year earlier, which dilutes existing holders. It passes 4 of our 7 financial-health checks.

Our model value for Lifestance Health Group is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Lifestance Health Group, Inc.'s trailing-twelve-month revenue grew 20.4% year on year, with a free-cash-flow margin of 11.0%.

Our discounted-cash-flow model values the business at ~$3.7 per share in the base case (~$2.8–$4.9 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 32% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 20.4% over the last 12 months.
  • Growth speeding up. The growth rate is 3.9 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 5.0 points on a year ago.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 9.9% over 90 days.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 2.0% in a year.
  • High earnings multiple. The shares trade at 103 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 52% and a beta of 0.6 against the S&P 500.
  • Insiders selling. 9 insiders sold $844M of stock over the past 365 days and none bought (1% under pre-set trading plans).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$0.11 against an average estimate of $0.08: beat by 32.4%
Revenue
$435m, up 26.1% on a year earlier
Share reaction
+4.5% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
total revenue $1.69bn to $1.73bn (full year 2026); center Margin $570m to $594m (full year 2026)
Next report
November 5, 2026; average EPS estimate $0.08

Lifestance Health Group's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.0%
  • 1 week+1.5%
  • 1 month+12.1%
  • This year+88.4%
  • 1 year+170.6%
  • 5 years+0.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.6B
Operating margin
4.9%
Net margin
3.2%
EPS (TTM, diluted)
$0.13

Growth

Revenue growth
+20.4%
Change in growth rate
+3.9 pts
Share count change
+2.0%

Cash

Free cash flow (TTM)
$174M
FCF margin
11.0%
Stock pay % of revenue
4.4%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Results
  7. Guidance
  8. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Lifestance Health Group, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Our value per share comes from a discounted-cash-flow model of Lifestance Health Group, Inc.'s free cash flow after stock-based pay ( $35.3M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Lifestance Health Group, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.74 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$3.7 ~$2.8–$4.9 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.6 ~$6.2–$11 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lifestance Health Group, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$9.52$4.94$7.83$7.37$7.04$13.26
Market value$3.1bn$1.8bn$2.9bn$2.8bn$2.8bn$5.2bn
+ Net debt (− = net cash)$13m$125m$211m$135m$34m$50m
Enterprise value$3.1bn$1.9bn$3.1bn$2.9bn$2.8bn$5.3bn
Multiples
Price / sales 4.7x2.0x2.7x2.2x1.9x3.3x
Price / earnings ————n/m102.8x
Price / free cash flow ———32.6x25.0x29.9x
EV / EBITDA ———n/m42.4x43.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

17 /100

Weak moat

How hard Lifestance Health Group's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -5.8% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -10.0%; its worst year was -46.8%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 6 years, at a median -1.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (22 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $432m and EPS of $0.08 (range $0.07 to $0.10) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.36 +97% $1.7bn +20%
Next $0.43 +20% $2.0bn +15%

Next year's EPS estimate has moved +9.9% in 90 days, across 5 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.08 $0.11 +32.4%
Mar 2026 $0.06 $0.07 +10.4%
Dec 2025 $0.05 $0.09 +64.3%
Sept 2025 $0.04 $0.01 −63.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • Total revenue full year 2026 $1.685bn to $1.725bn Raised
    “The Company is raising full year revenue to $1.685 billion to $1.725 billion, Center Margin to $570 million to $594 million, and Adjusted EBITDA to $215 million to $235 million.” source
  • total revenue third quarter of 2026 $420m to $440m
    “For the third quarter of 2026, the Company expects total revenue of $420 million to $440 million, Center Margin of $140 million to $152 million, and Adjusted EBITDA of $49 million to $59 million.” source
  • Center Margin full year 2026 $570m to $594m Non-GAAP Raised
    “The Company is raising full year revenue to $1.685 billion to $1.725 billion, Center Margin to $570 million to $594 million, and Adjusted EBITDA to $215 million to $235 million.” source
  • Adjusted EBITDA full year 2026 $215m to $235m Non-GAAP Raised
    “The Company is raising full year revenue to $1.685 billion to $1.725 billion, Center Margin to $570 million to $594 million, and Adjusted EBITDA to $215 million to $235 million.” source
  • Center Margin third quarter of 2026 $140m to $152m Non-GAAP
    “For the third quarter of 2026, the Company expects total revenue of $420 million to $440 million, Center Margin of $140 million to $152 million, and Adjusted EBITDA of $49 million to $59 million.” source
  • Adjusted EBITDA third quarter of 2026 $49m to $59m Non-GAAP
    “For the third quarter of 2026, the Company expects total revenue of $420 million to $440 million, Center Margin of $140 million to $152 million, and Adjusted EBITDA of $49 million to $59 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Lifestance Health Group, Inc.'s revenue by +16.7% next year and +17.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+15.7%, weight 51%) , management guidance (+15.5%, weight 21%) and the company's own record (+19.3%, weight 28%) . How the weights are set.

Analyst recommendations

11 analysts, Oct 2026
Buy982%
Hold218%
Sell00%

Monthly trend

  1. Oct 202627211
  2. Sep 202627211
  3. Aug 202627211
  4. Jul 202627211

Counts of recommendations published by analysts covering Lifestance Health Group, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.5%
of tradable shares
Days to cover
2.74
at average volume
Short interest, 1 month
+14%
to September 30, 2026
Held by institutions
91%
of shares
Held by insiders
3.1%
of shares
Employees
8,542
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +170.6%

$4.90 on October 31, 2025 to $13.26

ThenNowEffect
Revenue (last 12 months) $1.3bn $1.6bn +20.4%
P/S multiple 1.4x 3.3x +129.4%
Share count 385m 392m −2.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +117.0%

$6.11 on November 3, 2023 to $13.26

ThenNowEffect
Revenue (last 12 months) $959m $1.6bn +65.2%
P/S multiple 2.3x 3.3x +43.6%
Share count 359m 392m −8.6%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
LFST−48%+59%−6%−5%+88%
Industry peers (median)−25%+6%−6%−9%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
LFST58%67%50%42%64%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
LFST−61%−45%−45%−54%−17%
S&P 500−25%−10%−8%−19%−9%

Worst fall since June 10, 2021: 87% from July 7, 2021 to August 1, 2025. Getting back needed a 664% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.81 – $13.63
From 52-week high
−2.8%
vs 50-day average
+6.1%
vs 200-day average
+41.6%
Volatility (1 year)
53%
Beta vs S&P 500
0.55

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
9 up, 3 down
typical move ±8.5%
After a week
11 up, 1 down
typical move ±13.2%
After a month
6 up, 6 down
typical move ±18.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +4.5% +0.5% +17.8% +22.8%
May 7, 2026 +4.6% +0.5% +7.2% −0.3%
February 25, 2026 −2.5% +0.3% +2.7% −6.3%
November 6, 2025 +30.8% −1.0% +31.2% +33.3%
August 7, 2025 +12.1% +0.7% +43.1% +43.8%
May 7, 2025 −11.3% +1.1% −12.4% −10.8%
February 27, 2025 +3.7% −0.1% +4.9% −10.8%
November 7, 2024 +3.2% +1.2% +1.4% +4.2%
August 8, 2024 +1.6% +2.8% +6.0% +26.5%
May 9, 2024 −1.7% +0.7% +5.6% −23.4%
February 28, 2024 +24.6% +0.2% +8.1% −7.9%
February 2, 2024 +1.1% +0.7% +17.7% +30.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Lifestance Health Group, Inc.
$1B $1.2B $1.4B $1.6B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1B Revenue (TTM), FY23 Q4: $1.1B Revenue (TTM), FY24 Q1: $1.1B Revenue (TTM), FY24 Q2: $1.2B Revenue (TTM), FY24 Q3: $1.2B Revenue (TTM), FY24 Q4: $1.3B Revenue (TTM), FY25 Q1: $1.3B Revenue (TTM), FY25 Q2: $1.3B Revenue (TTM), FY25 Q3: $1.4B Revenue (TTM), FY25 Q4: $1.4B Revenue (TTM), FY26 Q1: $1.5B Revenue (TTM), FY26 Q2: $1.6B $1.6B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1B
FY23 Q4 $1.1B
FY24 Q1 $1.1B
FY24 Q2 $1.2B
FY24 Q3 $1.2B
FY24 Q4 $1.3B
FY25 Q1 $1.3B
FY25 Q2 $1.3B
FY25 Q3 $1.4B
FY25 Q4 $1.4B
FY26 Q1 $1.5B
FY26 Q2 $1.6B
Revenue growth, TTM YoY Lifestance Health Group, Inc.
10% 15% 20% 25% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 22.5% Revenue growth, TTM YoY, FY23 Q4: 22.8% Revenue growth, TTM YoY, FY24 Q1: 21.4% Revenue growth, TTM YoY, FY24 Q2: 20.6% Revenue growth, TTM YoY, FY24 Q3: 20.1% Revenue growth, TTM YoY, FY24 Q4: 18.5% Revenue growth, TTM YoY, FY25 Q1: 16.3% Revenue growth, TTM YoY, FY25 Q2: 13.9% Revenue growth, TTM YoY, FY25 Q3: 13.4% Revenue growth, TTM YoY, FY25 Q4: 13.9% Revenue growth, TTM YoY, FY26 Q1: 16.5% Revenue growth, TTM YoY, FY26 Q2: 20.4% 20.4%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 22.5%
FY23 Q4 22.8%
FY24 Q1 21.4%
FY24 Q2 20.6%
FY24 Q3 20.1%
FY24 Q4 18.5%
FY25 Q1 16.3%
FY25 Q2 13.9%
FY25 Q3 13.4%
FY25 Q4 13.9%
FY26 Q1 16.5%
FY26 Q2 20.4%
Operating margin (TTM) Lifestance Health Group, Inc.
-30% -20% -10% 0% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -20.2% Operating margin (TTM), FY23 Q4: -17.9% Operating margin (TTM), FY24 Q1: -15.6% Operating margin (TTM), FY24 Q2: -12.1% Operating margin (TTM), FY24 Q3: -5.4% Operating margin (TTM), FY24 Q4: -2.5% Operating margin (TTM), FY25 Q1: -1.0% Operating margin (TTM), FY25 Q2: -0.0% Operating margin (TTM), FY25 Q3: 0.5% Operating margin (TTM), FY25 Q4: 1.7% Operating margin (TTM), FY26 Q1: 3.0% Operating margin (TTM), FY26 Q2: 4.9% 4.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -20.2%
FY23 Q4 -17.9%
FY24 Q1 -15.6%
FY24 Q2 -12.1%
FY24 Q3 -5.4%
FY24 Q4 -2.5%
FY25 Q1 -1.0%
FY25 Q2 -0.0%
FY25 Q3 0.5%
FY25 Q4 1.7%
FY26 Q1 3.0%
FY26 Q2 4.9%
FCF margin (TTM) Lifestance Health Group, Inc.
-10% -5% 0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -3.7% FCF margin (TTM), FY23 Q4: -5.4% FCF margin (TTM), FY24 Q1: -6.2% FCF margin (TTM), FY24 Q2: -1.5% FCF margin (TTM), FY24 Q3: 2.9% FCF margin (TTM), FY24 Q4: 6.9% FCF margin (TTM), FY25 Q1: 8.0% FCF margin (TTM), FY25 Q2: 9.1% FCF margin (TTM), FY25 Q3: 8.7% FCF margin (TTM), FY25 Q4: 7.7% FCF margin (TTM), FY26 Q1: 9.5% FCF margin (TTM), FY26 Q2: 11.0% 11.0%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -3.7%
FY23 Q4 -5.4%
FY24 Q1 -6.2%
FY24 Q2 -1.5%
FY24 Q3 2.9%
FY24 Q4 6.9%
FY25 Q1 8.0%
FY25 Q2 9.1%
FY25 Q3 8.7%
FY25 Q4 7.7%
FY26 Q1 9.5%
FY26 Q2 11.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Lifestance Health Group took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $1.4B
  2. Selling, general and admin $382M · 26.8%
  3. Other operating costs $1B · 71.5%
  4. Operating income $24.1M · 1.7%
  5. Interest and other $11.8M · 0.8%
  6. Net income $9.7M · 0.7%

Shares of revenue. Source: Lifestance Health Group's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 213 668 860 1,056 1,251 1,424 1,585
EBITDA 18 −271 −181 −152 9 66 121
Operating income 15 −286 −210 −189 −32 24 78
Net income 6 −307 −216 −186 −57 10 51
Diluted EPS — — — — — — $0.13
Growth (year on year)
Revenue — +214.1% +28.8% +22.8% +18.5% +13.9% +20.4%
EBITDA — <−999% — — — — +193.1%
Operating income — <−999% — — — — —
Net income — <−999% — — — — —
Margins
EBITDA margin 8.6% −40.6% −21.1% −14.4% 0.7% 4.6% 7.6%
Operating margin 7.2% −42.9% −24.5% −17.9% −2.5% 1.7% 4.9%
Net margin 2.7% −46.0% −25.1% −17.6% −4.6% 0.7% 3.2%
Free-cash-flow margin 1.3% −12.7% −3.1% −5.4% 6.9% 7.7% 11.0%
Cash flow
Cash from operations 17 9 53 −17 107 146 218
Capital spending 14 94 79 41 22 36 44
Free cash flow 3 −85 −26 −57 86 110 174
Stock-based pay 0 259 187 99 76 75 70
Free cash flow after stock pay 3 −345 −214 −157 10 35 104
Balance sheet
Cash 3 148 109 79 155 249 226
Total debt 0 161 234 289 290 283 276
Net debt (negative = net cash) −3 13 125 211 135 34 50
Diluted shares — 328m 355m 367m 379m 391m 392m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 7 checks passed · June 30, 2026
What it owns · $2.2bn
Short-term assets $378mLonger-term assets $1.8bn
What it owes, and who funded it · $2.2bn
Short-term liabilities $275mLonger-term liabilities $430mShareholders' equity $1.5bn
  • Short-term assets cover short-term liabilities $378m of assets due within a year against $275m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $378m short-term assets against $430m of longer-dated liabilities.
  • More cash than debt $226m of cash against $273m of debt.
  • Debt below 40% of shareholders' equity Debt is 19% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 10% to 19% over five years.
  • A year's operating cash flow covers at least 20% of debt $218m of operating cash flow against $273m of debt.
  • Operating profit covers interest at least five times over Operating income of $78m against $10m of interest.

From Lifestance Health Group, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.0%
year over year
Sales & admin spending
25.2%
of revenue
Days sales outstanding
26 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated LFST PIII ADUS HQY PGNY EVH Median
Revenue, last 12 months $1.6bn $1.5bn $1.5bn $1.4bn $1.3bn $2.1bn $1.2bn
Revenue growth, last 12 months 20.4% 2.8% 15.9% 7.3% 5.5% −4.5% 7.4%
Revenue growth, 3-year average 18.2% 9.7% 13.9% 13.2% 11.0% 8.7% 11.5%
Revenue growth, latest quarter 26.1% 8.6% 8.0% 7.6% 5.3% 46.9% 8.6%
Gross margin — — 32.4% 71.2% 24.6% 17.2% 27.9%
Operating margin 4.9% −9.9% 10.0% 25.8% 8.6% −20.4% 2.6%
Operating margin, 3-year average −2.4% −14.7% 9.4% 19.9% 7.0% −8.0% 2.0%
Net margin 3.2% −6.6% 7.1% 17.4% 6.0% −24.1% 1.2%
Cash from operations / revenue 13.7% −8.7% 11.0% 36.0% 15.4% 2.6% 6.3%
Free-cash-flow margin 11.0% −8.7% 10.5% 35.8% 13.6% −2.7% 5.2%
Free-cash-flow margin, 3-year average 6.2% −7.1% 8.9% 30.8% 14.7% −2.3% 3.7%
Stock pay / revenue 4.4% 0.3% 1.2% 6.0% 8.2% 2.0% 1.1%
Change in share count 2.0% 40.0% 0.8% −3.3% −4.2% −2.4% 0.4%

Median of all 42 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$4B
Institutions reporting
284
Shares held vs prior quarter
▲ 2.2%
Positions opened / closed
82 / 28

Top buyers and sellers, Q2 2026: 198 institutions bought and 81 sold ; the biggest buyer was Blackrock, Inc (+18.2M shares) and the biggest seller Tpg Gp A, LLC (−28.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Tpg Gp A, LLC $1.2B 111.7M 29.6% ▼ 20.2%
FMR LLC $624M 58.3M 15.4% ▼ 0.7%
Blackrock, Inc. $389M 36.3M 9.6% ▲ 100.4%
Summit Partners L P $250M 23.3M 6.2% ▼ 20.2%
Vanguard Portfolio Management LLC $150M 14.0M 3.7% ▲ 44.2%
Jennison Associates LLC $129M 12.1M 3.2% ▲ 18.1%
Dimensional Fund Advisors LP $122M 11.4M 3.0% ▲ 10.2%
Vanguard Capital Management LLC $104M 9.7M 2.6% ▲ 23.1%
State Street Corp $88.1M 8.2M 2.2% ▲ 101.0%
UBS Am, A Distinct Business Unit Of UBS Asset Management Americas LLC $63.7M 5.9M 1.6% ▼ 2.4%
Geode Capital Management, LLC $59.9M 5.6M 1.5% ▲ 18.4%
Morgan Stanley $53.8M 5.0M 1.3% ▲ 45.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lifestance Health Group, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $844M 31 trades by 9 insiders · 1% under pre-set plans
Net ▼ $844M net selling
Insider Date Trade Shares Price Value
Tpg Gp A, Llc 10% owner September 11, 2026 Sell 18,409,705 $12.29 $226M
Paunovich Vukasin Chief Technology Officer September 2, 2026 Sell 42,067 $12.87 $541,402
Deluca Teresa Director August 14, 2026 Sell 7,500 $12.68 $95,100
Deluca Teresa Director August 13, 2026 Sell 20,441 $12.23 $249,993
Burdick Kenneth A Director August 11, 2026 Sell 500,000 $11.51 $5.8M
Miller Lisa K Chief Operating Officer August 10, 2026 Sell pre-set plan 47,912 $10.85 $519,845
Tpg Gp A, Llc 10% owner August 10, 2026 Sell 13,643,207 $10.62 $145M
Paunovich Vukasin Chief Technology Officer August 10, 2026 Sell pre-set plan 44,394 $10.85 $481,675
Bessler Robert Director June 26, 2026 Sell pre-set plan 447,168 $10.13 $4.5M
Bessler Robert Director June 26, 2026 Sell pre-set plan 447,169 $10.13 $4.5M
Tpg Gp A, Llc 10% owner May 12, 2026 Sell 28,281,943 $8.02 $227M
Black Darren M. Director May 12, 2026 Sell 5,899,661 $8.02 $47.3M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 25, 2026
  • November 6, 2025
  • August 7, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Lifestance Health Group, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Lifestance Health Group, Inc. in brief

What does Lifestance Health Group, Inc. do?
Lifestance Health Group, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Lifestance Health Group, Inc.'s stock ticker?
Lifestance Health Group, Inc. trades under the ticker LFST on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Lifestance Health Group, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Lifestance Health Group, Inc. reported revenue of $1.6B, 20.4% higher than a year earlier, according to its SEC filings.
What is Lifestance Health Group, Inc.'s free cash flow?
Lifestance Health Group, Inc.'s free-cash-flow margin is 11.0% of revenue over the trailing twelve months.
Who are Lifestance Health Group, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Tpg Gp A, LLC, FMR LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Lifestance Health Group, Inc.'s market cap?
On November 2, 2026, Lifestance Health Group, Inc.'s market capitalisation was about $5.2B, with a price-to-earnings ratio of 102.8 and net debt of $49.6M. Market figures come from third-party market data and may be delayed.
How much debt does Lifestance Health Group, Inc. have?
Lifestance Health Group, Inc.'s debt-to-equity ratio is 18.5%, from its latest balance sheet (10.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are Lifestance Health Group, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Lifestance Health Group, Inc. are P3 Health Partners Inc., Addus Homecare Corp, Healthequity, Inc., Progyny, Inc. and Evolent Health, Inc. The side-by-side comparison below sets their revenue, margins and growth against Lifestance Health Group, Inc.'s.
Are insiders buying or selling Lifestance Health Group, Inc. stock?
Over the last 12 months, Lifestance Health Group, Inc.'s directors and officers reported 0 open-market purchases and 31 sales on Form 4. The insider trading page charts every trade.
When is Lifestance Health Group, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Lifestance Health Group, Inc. announces its own schedule.